Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions.

Cella, David; Chen, Chieh-I; Quek, Ruben G W; Uribarren, Ainhoa; Reaney, Matthew; Mastey, Vera; Collyar, Deborah; Chassany, Olivier

Cella, David; Chen, Chieh-I; Quek, Ruben G W; Uribarren, Ainhoa; Reaney, Matthew; Mastey, Vera; Collyar, Deborah; Chassany, Olivier.

Afiliação

Cella D; Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Chen CI; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States.
Quek RGW; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States.
Uribarren A; IQVIA, Reading, United Kingdom.
Reaney M; IQVIA, Reading, United Kingdom.
Mastey V; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States.
Collyar D; Patient Advocates in Research (PAIR), Danville, CA, United States.
Chassany O; Health Economics Clinical Trial Unit (URC-ECO), Hôpital Hotel-Dieu, Paris, France.

Front Pharmacol ; 13: 1031992, 2022.

Article em En | MEDLINE | ID: mdl-36339622

Palavras-chave

PRO labeling; oncology; patient care; patient reported outcome instruments; quality of life

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Guideline / Health_technology_assessment / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google